<?xml version="1.0" encoding="UTF-8"?><ClinicalUseDefinition xmlns="http://hl7.org/fhir">
  <id value="example-indication"/>
  <meta>
    <security>
      <system value="http://terminology.hl7.org/CodeSystem/v3-ActReason"/>
      <code value="HTEST"/>
      <display value="test health data"/>
    </security>
  </meta>
  <contained>
    <Group>
      <id value="group"/>
      <type value="person"/>
      <membership value="definitional"/>
      <characteristic>
        <code>
          <coding>
            <system value="http://ema.europa.eu/example/characteristic"/>
            <code value="age-range"/>
          </coding>
        </code>
        <valueRange>
          <low>
            <value value="18"/>
            <unit value="a"/>
          </low>
        </valueRange>
        <exclude value="false"/>
      </characteristic>
    </Group>
  </contained>
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="brr"/>
  </extension>
  <type value="indication"/>
  <subject>
    <reference>
      <reference value="MedicinalProductDefinition/example"/>
    </reference>
  </subject>
  <!--  example product is indicated for Prevention of venous thromboembolic events  -->
  <indication>
    <diseaseSymptomProcedure>
      <concept>
        <coding>
          <system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/>
          <code value="Pulmonary-embolism-and-thrombosis-example-code"/>
        </coding>
        <text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."/>
      </concept>
    </diseaseSymptomProcedure>
    <diseaseStatus>
      <concept>
        <coding>
          <system value="http://ema.europa.eu/example/diseasestatus"/>
          <code value="Recurrent"/>
        </coding>
      </concept>
    </diseaseStatus>
    <intendedEffect>
      <concept>
        <coding>
          <system value="http://ema.europa.eu/example/intendedeffect"/>
          <code value="PRYLX"/>
        </coding>
      </concept>
    </intendedEffect>
  </indication>
  <population>
    <reference value="#group"/>
  </population>
</ClinicalUseDefinition>